High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.

MLA

Ferreri, Andrés J. M., et al. “High-Dose Cytarabine plus High-Dose Methotrexate versus High-Dose Methotrexate Alone in Patients with Primary CNS Lymphoma: A Randomised Phase 2 Trial.” Lancet, vol. 374, no. 9700, Oct. 2009, pp. 1512–20. EBSCOhost, https://doi.org/10.1016/S0140-6736(09)61416-1.

APA

Ferreri, A. J. M., Reni, M., Foppoli, M., Martelli, M., Pangalis, G. A., Frezzato, M., Cabras, M. G., Fabbri, A., Corazzelli, G., Ilariucci, F., Rossi, G., Soffietti, R., Stelitano, C., Vallisa, D., Zaja, F., Zoppegno, L., Aondio, G. M., Avvisati, G., Balzarotti, M., & Brandes, A. A. (2009). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet, 374(9700), 1512–1520. https://doi.org/10.1016/S0140-6736(09)61416-1

Chicago

Ferreri, Andrés J. M., Michele Reni, Marco Foppoli, Maurizio Martelli, Gerasimus A. Pangalis, Maurizio Frezzato, Maria Giuseppina Cabras, et al. 2009. “High-Dose Cytarabine plus High-Dose Methotrexate versus High-Dose Methotrexate Alone in Patients with Primary CNS Lymphoma: A Randomised Phase 2 Trial.” Lancet 374 (9700): 1512–20. doi:10.1016/S0140-6736(09)61416-1.